# EDGAR Filing Document

**Accession Number:** 0001624326
**File Stem:** 0001493152-25-017859
**Filing Date:** 2025-10
**Character Count:** 20815
**Document Hash:** 77236d6153e7d0525816c5e5091e9d59
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-017859.hdr.sgml**: 20251010

**ACCESSION NUMBER**: 0001493152-25-017859

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251010

**DATE AS OF CHANGE**: 20251010

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lucid Diagnostics Inc.
- **CENTRAL INDEX KEY:** 0001799011
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 825488042
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92965
- **FILM NUMBER:** 251389125

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212 949 4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PAVmed Inc.
- **CENTRAL INDEX KEY:** 0001624326
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471214177
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (212) 949-4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAXmed Inc.
- **DATE OF NAME CHANGE:** 20141105

## Exhibit 99.1

**Exhibit 99.1**

**FORM OF**

**IRREVOCABLE PROXY**

In connection with the issuance by Lucid Diagnostics Inc., a Delaware corporation (the "***Company***"), of shares of [common] / [restricted] stock of the Company (the "[***Common Stock***] / [***Restricted Stock***]") to the undersigned [officer] / [stockholder] of the Company (the "***[Officer] / [Stockholder]***") on or about the date hereof, the [Officer] / [Stockholder] agrees as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. Grant of Irrevocable Proxy.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The [Officer] / [Stockholder], with respect to all shares of capital stock now owned (or in the future that may be owned) by the [Officer] / [Stockholder] in the Company (including, without limitation, the shares of [Common Stock] / [Restricted Stock]) (collectively, the "***Shares***") hereby grants to PAVmed Inc., a Delaware corporation (the "***Proxy Holder***"), an irrevocable proxy under Section 212 of the Delaware General Corporation Law to vote the Shares in any manner that the Proxy Holder may determine in its sole and absolute discretion to be in the Proxy Holder's own best interest, at any meeting of shareholders of the Company or in respect of any written consent of shareholders with respect to any matter or the transactions contemplated thereby[; *provided, however*, that the rights granted by the [Officer] / [Stockholder] to the Proxy Holder contained herein shall not permit the Proxy Holder to vote, and the [Officer] / [Stockholder] reserves the right to vote, with respect to any matter that would (i) amend, alter or repeal any provision of the Certificate of Designation of Preferences, Rights and Limitation of Series [X] Convertible Preferred Stock of the Company (the "***Certificate of Designations***") in a manner that adversely affects the powers, preferences or rights of the Series [X] Preferred Stock, (b) increase the number of authorized shares of Series [X] Preferred Stock or (c) result in the issuance, or obligate the Company to issue, shares of any additional class or series of capital stock unless the same ranks junior or pari passu to the Series [X] Preferred Stock with respect to the distribution of assets on liquidation]. It is expressly understood and agreed that the foregoing irrevocable proxy [is hereby granted to the Proxy Holder by the Officer in partial consideration of the issuance of the shares of Restricted Stock and of the Company's continued employment of the Officer, and] is coupled with an interest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Proxy Holder shall have no duty, liability and obligation whatsoever to the [Officer] / [Stockholder] arising out of the exercise by the Proxy Holder of the foregoing irrevocable proxy. The [Officer] / [Stockholder] expressly acknowledges and agrees that (i) the [Officer] / [Stockholder] will not interfere with the exercise of the Proxy Holder's rights under the irrevocable proxy and (ii) the [Officer] / [Stockholder] waives and relinquishes any claim, right or action the [Officer] / [Stockholder] might have, as a shareholder of the Company or otherwise, against the Proxy Holder or any of its affiliates in connection with any exercise of the irrevocable proxy granted hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The [Officer] / [Stockholder] has the right to notice of any and all special and general meetings of shareholders during the term of this Irrevocable Proxy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) [This irrevocable proxy shall automatically expire as to all Shares on the date that the Officer ceases to be an employee, officer or director of the Company.] In addition, this irrevocable proxy shall automatically expire as to any Shares upon the [Officer] / [Stockholder] ceasing to own the same.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Legend.** The [Officer] / [Stockholder] agrees to permit an appropriate legend on certificates evidencing the Shares reflecting the grant of the irrevocable proxy contained in the foregoing Section 1. The Proxy Holder shall cooperate with the [Officer] / [Stockholder] with respect to any requests to remove such legend in connection with any disposition by the [Officer] / [Stockholder] of the Shares (including, without limitation, dispositions pursuant to an authorized 10b5-1 program or dispositions made to satisfy tax withholding tax obligations).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Representations and Warranties.** The [Officer] / [Stockholder] represents and warrants to the Proxy Holder as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The [Officer] / [Stockholder] has all necessary rights, power and authority to execute, deliver and perform his obligations under this Irrevocable Proxy. This Irrevocable Proxy has been duly executed and delivered by the [Officer] / [Stockholder] and constitutes a legal and valid obligation enforceable against the [Officer] / [Stockholder] in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The [Officer] / [Stockholder] is the record owner of the Shares; there are no proxies, voting trusts or other agreements or understandings to which such [Officer] / [Stockholder] is a party or bound by and which expressly require that any of the Shares be voted in any specific manner, other than this Irrevocable Proxy; and such [Officer] / [Stockholder] has not entered into, and will not enter into, any agreement or arrangement inconsistent with this Irrevocable Proxy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. Equitable Remedies.** The [Officer] / [Stockholder] acknowledges that irreparable damage would result if this Irrevocable Proxy is not specifically enforced and that, therefore, the rights and obligations of the Proxy Holder may be enforced by a decree of specific performance issued by a court of competent jurisdiction, and appropriate injunctive relief may be applied for and granted in connection therewith. Such remedies shall, however, not be exclusive and shall be in addition to any other remedies which the Proxy Holder may otherwise have available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. Governing Law; Dispute Resolution.** This Irrevocable Proxy shall be governed by and construed in accordance with the laws of the State of New York (without regard to choice of law provisions). [Any dispute arising hereunder shall be subject to resolution in accordance with the dispute resolution procedures set forth in the Officer's employment agreement with the Company.] This Irrevocable Proxy may be executed in any number of counterparts (including by facsimile, pdf or other electronic document transmission), each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. This Irrevocable Proxy contains the entire agreement between the parties with respect to the matters addressed herein and supersedes all prior oral or written agreements and understandings, if any, relating to the subject matter hereof.

[*signature page follows*]

IN WITNESS WHEREOF, the undersigned have executed this Irrevocable Proxy on this __th day of ________.

---

| |
|:---|
| By: |
| Name: |

---

Acknowledged and agreed to:

PAVMED INC.

By:   <br> Name: <br> Title:

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 5)**

**Lucid Diagnostics Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**54948X109**

*(CUSIP Number)*

**Lishan Aklog, M.D.**<br>360 MADISON AVENUE, 25TH FLOOR<br>NEW YORK NY 10017<br>917-813-1828

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/09/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **54948X109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**PAVmed Inc.** | Name of reporting person<br>**PAVmed Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**38816903.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**31302444.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**38816903.00** | Aggregate amount beneficially owned by each reporting person<br>**38816903.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**28.3%** | Percent of class represented by amount in Row (11)<br>**28.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** This Amendment No. 5 (this "Amendment") to the Schedule 13D, which was originally filed on October 27, 2021 and was previously amended on December 2, 2022, February 2, 2024, February 20, 2024 and December 12, 2024 (as amended to date, this "Schedule 13D"), is filed on behalf of PAVmed Inc., a Delaware corporation (the "Reporting Person"), with respect to the common stock, par value $0.001 per share ("Common Stock"), of Lucid Diagnostics Inc. (the "Issuer"). Except as modified or supplemented by this Amendment, the Schedule 13D as in effect prior to this Amendment remains unchanged. Capitalized terms used but not defined in this Amendment have the meanings ascribed to them in the Schedule 13D as in effect prior to this Amendment.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Lucid Diagnostics Inc.

**(c) Address of Issuer's Principal Executive Offices:**
360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NY, 10017

**Item 4. Purpose of Transaction**

The Reporting Person is the parent company of the Issuer. As a result of its ability to vote 28.3% of the Common Stock (and an estimated 27.2% of all the capital stock of the Issuer), the Reporting Person has the power to significantly influence the election of directors and all other matters that would require the vote of the outstanding shares of capital stock of the Issuer. Subject to the restrictions on transfer described in Item 6, the Reporting Person or any of the Principals, respectively, may acquire additional securities of the Issuer and may sell all or a portion of the securities then held in the open market or in privately negotiated transactions, although none of the Reporting Person or the Principals has any present intention to acquire or sell any securities of the Issuer except as described in Item 6. Each of the Reporting Person and each of the Principals, respectively, intends to review its ownership of the Issuer on a continuing basis. Any actions the Reporting Person or any Principal might undertake with respect to the Common Stock may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments relating to the Reporting Person, the Principals and/or the Issuer.

Other than as described above, and except in accordance with the Reporting Person's role as the parent company of the Issuer and the Principals' roles as officers and directors of the Reporting Person and the Issuer, the Reporting Person and Principals do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Reporting Person:
38,816,903 shares, 28.3%

Dr. Aklog:
1,541,627 shares, 1.1%

Mr. McGrath:
1,393,569 shares, 1.0%

Mr. O'Neil:
876,763 shares, 0.6%

Mr. Gordon:
900,000 shares, 0.7%

Mr. Glennon:
422,432 shares, 0.3%

Dr. Agrawal:
0 shares, 0.0%

Mr. Baxter:
0 shares, 0.0%

Mr. Sparks:
504,376 shares, 0.4%

Ms. White:
440,716 shares, 0.3%

**(b)**
Reporting Person:
Sole voting power: 38,816,903 shares
Sole dispositive power: 31,302,444 shares
Shared voting and dispositive power: 0 shares

Dr. Aklog:
Sole voting power: 0 shares
Sole dispositive power: 1,541,627 shares
Shared voting and dispositive power: 0 shares

Mr. McGrath:
Sole voting power: 0 shares
Sole dispositive power: 1,393,569 shares
Shared voting and dispositive power: 0 shares

Mr. O'Neil:
Sole voting power: 0 shares
Sole dispositive power: 876,763 shares
Shared voting and dispositive power: 0 shares

Mr. Gordon:
Sole voting power: 0 shares
Sole dispositive power: 900,000 shares
Shared voting and dispositive power: 0 shares

Mr. Glennon:
Sole voting and dispositive power: 422,432 shares
Shared voting and dispositive power: 0 shares

Dr. Agrawal:
Sole voting and dispositive power: 0 shares
Shared voting and dispositive power: 0 shares

Mr. Baxter:
Sole voting and dispositive power: 0 shares
Shared voting and dispositive power: 0 shares

Mr. Sparks:
Sole voting and dispositive power: 504,376 shares
Shared voting and dispositive power: 0 shares

Ms. White:
Sole voting and dispositive power: 440,716 shares
Shared voting and dispositive power: 0 shares

**(c)**
None, except as described in Item 3 above.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The Reporting Person entered into an agreement, dated as of October 9, 2025 ("Voting Agreement"), with a stockholder of the Issuer, pursuant to which such stockholder granted the Reporting Person a voting proxy over the shares of the Issuer's capital stock owned by such person, covering shares of Common Stock representing 3,177,500 votes and other shares of capital stock representing 3,862,911 votes. The Reporting Person previously entered into voting agreements with certain of the officers of the Issuer, covering shares of Common Stock representing 4,336,959 votes.

The Reporting Person also is party to (i) an exchange agreement with the holder of all its outstanding 7.875% Senior Secured Convertible Notes Due 2025 (the "Holder"), dated November 15, 2024 (the "Debt Exchange Agreement"), (ii) a security and pledge agreement with the Holder, dated as of April 4, 2022 (the "Security and Pledge Agreement"), (iii) a management services agreement with the Issuer, dated as of May 12, 2018 and most recently amended as of May 12, 2025 (the "MSA"), and (iv) a payroll and benefit expense reimbursement agreement with the Issuer, dated as of November 30, 2022 (the "PBERA"), each of which contain obligations relating to the acquisition, transfer or voting of the Common Stock. In addition, the Reporting Person undertook certain voting obligations in connection with the sale by the Issuer of convertible notes pursuant to a securities purchase agreement, dated as of November 12, 2024 (the "Issuer Note SPA"). The Debt Exchange Agreement and Security and Pledge Agreement are described in the Reporting Person's Current Reports on Form 8-K filed on April 4, 2022 and November 21, 2024, the MSA and PBERA are described in the Issuer's Annual Report on Form 10-K filed on March 24, 2025, and the obligations in connection with the Issuer Note SPA are described in Amendment No. 4 to this Schedule 13D filed on December 12, 2024, and such descriptions are incorporated herein by reference.

Certain of the Principals have been granted restricted stock and/or stock option awards as compensation by the Issuer, which awards provide for the acquisition of Common Stock in the case of the options, and which awards are subject to vesting and restrictions on transfer, all pursuant to the applicable award agreement. In addition, in connection with an underwritten offering of Common Stock by the Issuer on September 10, 2025, each of Dr. Aklog, Mr. McGrath, Mr. O'Neil, Mr. Gordon, Mr. Sparks and Ms. White entered into a lockup agreement, providing for restrictions on transfer of the Common Stock held by them for a period of 45 days.

The foregoing summaries of the Voting Agreements, Debt Exchange Agreement, Security and Pledge Agreement, MSA and PBERA are qualified in their entirety by reference to the full text of the agreements, which are attached or incorporated by reference as Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** PAVmed Inc.

**Signature:** /s/ Lishan Aklog, M.D.

**Name/Title:** Lishan Aklog, M.D.

**Date:** 10/10/2025